KCM
IDXG

Kennedy Capital Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Kennedy Capital Management’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,562
Closed -$615K – 801
2014
Q3 		$615K Sell
2,562
-1,443
-36% -$482K 0.01% 700
2014
Q2 		$1.75M Buy
4,005
+141
+4% +$65.1K 0.03% 575
2014
Q1 		$1.77M Buy
3,864
+80
+2% +$41.6K 0.03% 562
2013
Q4 		$1.82M Buy
3,784
+1,539
+69% +$752K 0.03% 571
2013
Q3 		$1.08M Buy
2,245
+1,099
+96% +$527K 0.02% 631
2013
Q2 		$539K Buy
+1,146
New +$520K 0.01% 689

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
LCM
Leonard Capital Management Vero Beach, Florida $5.25M AUM
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Kennedy Capital Management's IDXG Position: Q4 2014 in Review

Kennedy Capital Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2014, closing a stake of 2,562 shares — an estimated $615K sold.

Kennedy Capital Management first reported a position in IDXG in Q2 2013 and held it in 6 quarters. The position peaked at $1.82M in Q4 2013. 26 funds tracked by Wall St. Rank hold IDXG as of Q4 2014.

  • Kennedy Capital Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Kennedy Capital Management sold 2,562 Interpace Biosciences, Inc. Common Stock shares in Q4 2014, an estimated $615K.
  • Kennedy Capital Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
  • Kennedy Capital Management's Interpace Biosciences, Inc. Common Stock position peaked at $1.82M in Q4 2013.
  • 26 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2014.

Based on Kennedy Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.